Blue Trust Inc. Has $158,000 Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Blue Trust Inc. boosted its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 24.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 2,190 shares of the company’s stock after purchasing an additional 435 shares during the period. Blue Trust Inc.’s holdings in Prestige Consumer Healthcare were worth $158,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Northwestern Mutual Wealth Management Co. lifted its position in shares of Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after buying an additional 433 shares during the last quarter. nVerses Capital LLC boosted its position in Prestige Consumer Healthcare by 200.0% during the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares during the period. Huntington National Bank increased its holdings in shares of Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares during the last quarter. International Assets Investment Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 7,112.5% during the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock worth $83,000 after buying an additional 1,138 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Prestige Consumer Healthcare by 49.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,163 shares of the company’s stock worth $84,000 after buying an additional 387 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the transaction, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 over the last ninety days. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Trading Up 0.1 %

Shares of NYSE:PBH opened at $75.90 on Thursday. The business’s 50 day simple moving average is $79.29 and its 200 day simple moving average is $75.25. Prestige Consumer Healthcare Inc. has a 1 year low of $60.00 and a 1 year high of $86.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The company has a market capitalization of $3.75 billion, a P/E ratio of 18.47, a P/E/G ratio of 2.15 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same period in the prior year, the firm posted $1.07 EPS. Prestige Consumer Healthcare’s quarterly revenue was down .9% on a year-over-year basis. On average, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.46 EPS for the current fiscal year.

Analyst Ratings Changes

PBH has been the topic of several research analyst reports. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Finally, DA Davidson reiterated a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $85.25.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.